The Montreal-Boston Collaborative group co-founded the NIDDK IBD Genetics Consortium in 2002. Since then, our group has played a pivotal role in the identification of >150 genetic risk factors for IBD and made significant advances in the understanding their role in health and disease. The current proposal is meant to build on our successes and to support (1) our recruitment of IBD patients and healthy controls for the publicly-available NIDDK Repository, (2) our efforts to identify key genetic risk factors for IBD, and (3) our innovative work in understanding the biological basis of IBD. There is no doubt that the success of the genome-wide association studies (GWAS) in identifying genetic risk factors for IBD (>150 independent risk factors) presents us with new challenges to be faced in the years ahead. The primary challenge is how we can translate these genetic discoveries into a more comprehensive biological understanding of IBD pathogenesis. What is equally clear, although there are some notable exceptions (e.g. IL23R, ATG16L1) GWA studies have not directly led to the causal genes or specific functional variants, and this has greatly limited the ability to extract causal biology from these discoveries. Recently, however, we have demonstrated conclusively how sequencing of IBD genes has led to (1) the identification of the causal gene within regions harboring multiple candidates, and (2) the identification of rarer, higher penetrance alleles with more obvious functional consequence than the low penetrance, non- coding variants that have led to the discovery of these regions. These are critical steps for the genetic study of IBD as they will enable us to interpret the biological insight from the GWAS findings much more directly and precisely, providing a bridge from GWAS associations to functional biology. We have two main objectives: (1) To develop patient and control resources that will enhance the Consortium's capacity to identify genes, genetic variation and biological mechanisms contributing to the pathogenesis of IBD, and (2) To obtain a biologic understanding how specific rare genetic variants in associated genes predispose or protect an individual from developing IBD. In order to meet our first objective, we will take advantage of our network of >10 university-based hospitals with dedicated IBD clinics that has a proven track record of 10+ years in the recruitment of individuals for IBD genetic studies for the NIDDK IBD Genetics Consortium and the publicly-available NIDDK Repository. For our second objective, we will combine unique state-of-the-art gene sequencing data and genome-wide genetic data in order to identify rare causal genetic variation and innovative integrative biology approaches to demonstrate the role that this genetic variation has in determining why some individuals develop IBD and why others are protected from these diseases.
The Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, are characterized by chronic relapsing inflammation of the gastrointestinal trat and have an important impact on health, economic and social welfare systems, as a consequence of the morbidity associated with these diseases. IBD can affect anyone at any age with the majority of cases being diagnosed in adolescents and young adults;this is a crucial time of life for an individual's education, the ability to establish a stable financial footing andto launch a career and family. The Montreal-Boston Collaborative Group has, over the last ten years, played a pivotal role within the NIDDK IBD Genetics Consortium in the identification of >150 genetic risk factors for IBD and made significant advances in the understanding their role in health and disease. The current proposal is to support (1) our recruitment of IBD patients and healthy controls for the publicly-available NIDDK Repository, (2) our efforts to identify key genetic risk factors for IBD, and (3) our innovative work in understanding the biological basis of IBD.
|Ananthakrishnan, Ashwin N; Nguyen, Deanna D; Sauk, Jenny et al. (2014) Genetic polymorphisms in metabolizing enzymes modifying the association between smoking and inflammatory bowel diseases. Inflamm Bowel Dis 20:783-9|
|Ananthakrishnan, Ashwin N; Huang, Hailiang; Nguyen, Deanna D et al. (2014) Differential effect of genetic burden on disease phenotypes in Crohn's disease and ulcerative colitis: analysis of a North American cohort. Am J Gastroenterol 109:395-400|
|Liu, Jimmy Z; Hov, Johannes Roksund; Folseraas, Trine et al. (2013) Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 45:670-5|
|Lazarev, Mark; Huang, Chengrui; Bitton, Alain et al. (2013) Relationship between proximal Crohn's disease location and disease behavior and surgery: a cross-sectional study of the IBD Genetics Consortium. Am J Gastroenterol 108:106-12|
|Knights, Dan; Lassen, Kara G; Xavier, Ramnik J (2013) Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 62:1505-10|
|Beaudoin, Mélissa; Goyette, Philippe; Boucher, Gabrielle et al. (2013) Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genet 9:e1003723|
|Ananthakrishnan, A N; Oxford, E C; Nguyen, D D et al. (2013) Genetic risk factors for Clostridium difficile infection in ulcerative colitis. Aliment Pharmacol Ther 38:522-30|
|Kuballa, Petric; Nolte, Whitney M; Castoreno, Adam B et al. (2012) Autophagy and the immune system. Annu Rev Immunol 30:611-46|
|Rivas, Manuel A; Beaudoin, Melissa; Gardet, Agnes et al. (2011) Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 43:1066-73|
|Anderson, Carl A; Boucher, Gabrielle; Lees, Charlie W et al. (2011) Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43:246-52|
Showing the most recent 10 out of 41 publications